Akeso and Summit Therapeutics reported that ivonescimab, a PD‑1xVEGF bispecific, reduced the risk of progression or death by roughly 40% versus a PD‑1 blocker in a Chinese frontline lung cancer study, prompting optimism for broader registrational plans. The readout raises expectations that the bispecific could shift first‑line treatment if replicated in global trials. The Chinese Phase 3 cohort drove a substantial progression‑free survival advantage on top of chemotherapy; sponsors noted the result will inform the design of ongoing global trials that could challenge existing PD‑1‑based regimens. Investigators highlighted the drug’s dual mechanism as a potential driver of the effect. Regulatory regulators, especially those in markets running parallel registrational studies, will scrutinize safety, cross‑trial comparisons and biomarker data when assessing global approval pathways.